In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir

Antiviral Therapy

Volumn 9, Issue 3, 2004, Pages 353-363

  Lada, Olivier ^a   Benhamou, Yves ^a   Cahour, Annie ^a   Katlama, Christine ^a   Poynard, Thierry ^a   Thibault, Vincent ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; TENOFOVIR; TENOFOVIR DISOPROXIL;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENETIC SUSCEPTIBILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LIVER CIRRHOSIS; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS GENOME; VIRUS MUTANT; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; WILD TYPE;

ADENINE; ADULT; ANTIVIRAL AGENTS; CELL LINE; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; LAMIVUDINE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TRANSFECTION; VIRUS REPLICATION;

EID: 3042811705     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP & Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. Journal of Hepatology 1997; 27:18-24.
2. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D & Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310.
3. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL & Gray DE A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. New England Journal of Medicine 1998; 339:61-68.
4. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C & Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. New England Journal of Medicine 1995; 333:1657-1661.
5. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N & Condreay LD. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:1670-1677.
6. Ying C, de Clercq E & Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. Journal of Viral Hepatitis 2000; 7:79-83.
7. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T & Opolon P. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Annals of Internal Medicine 1996; 125:705-712.
8. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S & Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172-180.
9. Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C & Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306.
10. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER & Brown NA. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20-22.
11. Ladner SK, Miller TJ & King RW. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′- rhiacytidine and a reduced ability to synthesize viral DNA. Antimicrobial Agents & Chemotherapy 1998; 42:2128-2131.
12. Lin X, Yuan ZH, Wu L, Ding JP & Wen YM. A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency. Journal of Virology 2001; 75:11827-11833.
13. Melegari M, Scaglioni PP & Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-633.
14. Thibault V, Benhamou Y, Seguret C, Bochet M, Katlama C, Bricaire F, Opolon P, Poynard T & Agut H. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. Journal of Clinical Microbiology 1999; 37:3013-3016.
15. Cooley L, Ayres A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, Locarnini S & Sasadeusz J. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003; 17:1649-1657.
16. Delaney WE, Yang IVH, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD & Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. Journal of Virology 2003; 77:11833-11841.
17. Westland CE, Yang H, Namini H, L N, Gibbs CS, Miller MD, Fry J, B CL & X S. Comparison of anti-HBV activity of adefovir against different lamivudine-resistant HBV strains in vitro and in liver transplant patients. Hepatology 2001; 34:446A.
18. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I & Holy A. Antiviral activity of phosphonyl-methoxyalkyl derivatives of purine and pyrimidines. Antiviral Research 1987; 8:261-272.
19. Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S & Kahn JO. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy) propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrobial Agents & Chemotherapy 1998; 42:2380-2384.
20. Xiong X, Flores C, Yang H, Toole JJ & Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:1669-1673.
21. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, Lamy P & Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129-134.
22. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ & Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. Journal of Clinical Investigation 2001; 107:449-455.
23. Xiong S, Yang H, Westland C, Delaney W, Colledge D, Bartholomeusz A, Thibault V, Benhamou Y, Angus P, Kitis G, Wulfsohn M, Gibbs C, Fry J, Brosgart C & Locarnini S. Resistance surveillance of HBeAg-chronic hepatitis B patients treated for two years with adefovir dipivoxil. Journal of Hepatology 2003; 38:182.
24. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A & Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297.
25. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, Chen SS, Miller MD, Isaacson E, Cheng AK & Study T. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002; 16:1257-1263.
26. Tarantal AF, Marthas ML, Shaw JP, Cundy K & Bischofberger N. Administration of 9-[2-(R)-(phosphonomethoxy) propyl] adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1999; 20:323-333.
27. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J & Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16:2352-2354.
28. Van Bommel F, Schernick A, Hopf U & Berg T. Tenofovir disoproxil fumarate exhibits strong antivira effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003; 124:586-587.
29. Benhamou Y, Tubiana R & Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. New England Journal of Medicine 2003; 348:177-178.
30. Gunther S, Li BC, Miska S, Kruger DH, Meisel H & Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. Journal of Virology 1995; 69:5437-5444.
31. Pas SD, Fries E, De Man RA, Osterhaus AD & Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. Journal of Clinical Microbiology 2000; 38:2897-2901.
32. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL & Schinazi RF. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751-757.
33. Gunther S, Sommer G, Von Breunig F, Iwanska A, Kalinina T, Sterneck M & Will H. Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations. Journal of Clinical Microbiology 1998; 36:531-538.
34. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C & King RW. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrobial Agents & Chemotherapy 1997; 41:1715-1720.
35. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ & Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 1999; 29:939-945.
36. Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, Isom H, Furman P & Locarnini S. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrobial Agents & Chemotherapy 2001; 45:2495-2501.
37. Delaney WEt, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, Isom HC, Bock CT, Manns MP, Trautwein C & Locarnini S. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrobial Agents & Chemotherapy 2001; 45:1705-1713.
38. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J & Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New England Journal of Medicine 2003; 348:800-807.
39. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J & Brosgart CL. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New England Journal of Medicine 2003; 348:808-816.
40. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, Gibbs CS, Brosgart C, Fry J, Namini H, Katlama C & Poynard T. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718-723.
41. van Bommel F, Wunsche T, Schurmann D & Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36:507-508.
42. Ristig MB, Crippin J, Aberg JA, Powderly WG, Lisker-Melman M, Kessels L & Tebas P. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. Journal of Infectious Diseases 2002; 186:1844-1847.
43. Bruno R, Sacchi P, Zocchetti C, Ciappina V, Puoti M & Filice G. Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS 2003; 17:783-784.
44. Heijtink RA, Kruining J, de Wilde GA, Balzarini J, De Clercq E & Schalm SW. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrobial Agents & Chemotherapy 1994; 38:2180-2182.
45. Yin C, De Clercq E, Nicholson W, Furman P & Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. Journal of Viral Hepatitis 2000; 7:161-165.
46. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WEt, Isom H, Bowden S, Desmond P & Locarnini SA. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37:27-35.
47. De Clercq E. Perspectives for the treatment of hepatitis B virus infections. International Journal of Antimicrobial Agents 1999; 12:81-95.
48. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG & Arnold E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). Journal of Virology 2001; 75:4771-4779.